Skip to main content
. 2023 May 26;13:1107237. doi: 10.3389/fcimb.2023.1107237

Table 3.

The pooling results of the therapy and prognosis of CMVR in aIDS patients.

Category No. of studies Pooled incidence 95% CI P-value I 2 Sensitivity analysis Selected model
Anti-HIV therapy during the entire courses
cART 72 85% 76% 93% P<0.01 98% Negative Random-effect model
ART, no cART 31 6% 1% 14% P<0.01 95% Negative Random-effect model
No ART 51 9% 4% 15% P<0.01 95% Negative Random-effect model
Anti-CMV therapy
Systemic 118 45% 42% 48% P<0.01 98% Negative Random-effect model
Local 69 35% 29% 40% P<0.01 99% Negative Random-effect model
Combinational 20 20% 11% 29% P<0.01 99% Negative Random-effect model
Prognosis
                CMVR remission
Intraocular ganciclovir implant 2 89% 42% 100% P<0.01 96% Negative Random-effect model
Intravitreal ganciclovir 4 83% 57% 99% P<0.01 78% Negative Random-effect model
Intravenous ganciclovir 11 90% 79% 98% P<0.01 88% Negative Random-effect model
Intravenous and intravitreal ganciclovir 3 72% 39% 97% P=0.04 68% Negative Random-effect model
Intravitreal foscarnet 3 72% 28% 100% P<0.01 88% Negative Random-effect model
Intravenous foscarnet 3 92% 83% 98% P=0.75 0% Negative Fixed-effect model
               CMVR progression
Intraocular ganciclovir implant 6 17% 11% 24% P=0.02 64% Negative Random-effect model
Intravitreal ganciclovir 5 37% 3% 81% P<0.01 97% Negative Random-effect model
Intravenous ganciclovir 15 37% 24% 52% P<0.01 92% Negative Random-effect model
Oral ganciclovir 4 56% 23% 86% P<0.01 98% Negative Random-effect model
Intravenous foscarnet 3 7% 2% 13% P=0.87 0% Negative Fixed-effect model
Intravitreal cidofovir 2 9% 4% 16% P=0.21 36% Negative Fixed-effect model
Intravenous cidofovir 2 52% 41% 63% P=0.16 48% Negative Fixed-effect model
CMVR recurrence after discontinuing maintenance anti-CMV therapy 7 16% 4% 31% P<0.01 78% Negative Random-effect model
All-cause mortality 46 36% 28% 44% P<0.01 96% Negative Random-effect model
Incidence of IRU a 28 26% 19% 34% P<0.01 95% Negative Random-effect model
a

IRU represents an increase in or new-onset of intraocular inflammation in the anterior chamber or vitreous of an eye with CMVR coincident with immune recovery after initiating cART.

AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; cART, combination antiretroviral therapy; CI, confidence interval; CMV, cytomegalovirus; CMVR, cytomegalovirus retinitis; IRU, immune recovery uveitis.